Cargando…

Liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease

BACKGROUND AND AIMS: Liver fibrosis predicts adverse clinical outcomes, such as liver-related death (LRD) and hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD). We aimed to investigate the accuracy of semi-automated quantification of collagen proportionate are...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhengyi, Jeffrey, Gary P., Huang, Yi, De Boer, Bastiaan, Garas, George, Wallace, Michael, Bertot, Luis, Adams, Leon A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522738/
https://www.ncbi.nlm.nih.gov/pubmed/37358741
http://dx.doi.org/10.1007/s12072-023-10564-3
_version_ 1785110418109235200
author Wang, Zhengyi
Jeffrey, Gary P.
Huang, Yi
De Boer, Bastiaan
Garas, George
Wallace, Michael
Bertot, Luis
Adams, Leon A.
author_facet Wang, Zhengyi
Jeffrey, Gary P.
Huang, Yi
De Boer, Bastiaan
Garas, George
Wallace, Michael
Bertot, Luis
Adams, Leon A.
author_sort Wang, Zhengyi
collection PubMed
description BACKGROUND AND AIMS: Liver fibrosis predicts adverse clinical outcomes, such as liver-related death (LRD) and hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD). We aimed to investigate the accuracy of semi-automated quantification of collagen proportionate area (CPA) as an objective new method for predicting clinical outcomes. METHOD: Liver biopsies from patients with NAFLD underwent computerized image morphometry of Sirius Red staining with CPA quantification performed by ImageScope. Clinical outcomes, including total mortality, LRD, and combined liver outcomes (liver decompensation, HCC, or LRD), were determined by medical records and population-based data-linkage. The accuracy of CPA for predicting outcomes was compared with non-invasive fibrosis tests (Hepascore, FIB-4, APRI). RESULTS: A total of 295 patients (mean age 50 years) were followed for a median (range) of 9 (0.2–25) years totalling 3253 person-years. Patients with CPA ≥ 10% had significantly higher risks for total death [hazard ratio (HR): 5.0 (1.9–13.2)], LRD [19.0 (2.0–182.0)], and combined liver outcomes [15.6 (3.1–78.6)]. CPA and pathologist fibrosis staging (FS) showed similar accuracy (AUROC) for the prediction of total death (0.68 vs. 0.70), LRD (0.72 vs. 0.77) and combined liver outcomes (0.75 vs. 0.78). Non-invasive serum markers Hepascore, APRI, and FIB-4 reached higher AUROC; however, they were not statistically significant compared to that of CPA except for Hepascore in predicting total mortality (0.86 vs. 0.68, p = 0.009). CONCLUSION: Liver fibrosis quantified by CPA analysis was significantly associated with clinical outcomes including total mortality, LRD, and HCC. CPA achieved similar accuracy in predicting outcomes compared to pathologist fibrosis staging and non-invasive serum markers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12072-023-10564-3.
format Online
Article
Text
id pubmed-10522738
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer India
record_format MEDLINE/PubMed
spelling pubmed-105227382023-09-28 Liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease Wang, Zhengyi Jeffrey, Gary P. Huang, Yi De Boer, Bastiaan Garas, George Wallace, Michael Bertot, Luis Adams, Leon A. Hepatol Int Original Article BACKGROUND AND AIMS: Liver fibrosis predicts adverse clinical outcomes, such as liver-related death (LRD) and hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD). We aimed to investigate the accuracy of semi-automated quantification of collagen proportionate area (CPA) as an objective new method for predicting clinical outcomes. METHOD: Liver biopsies from patients with NAFLD underwent computerized image morphometry of Sirius Red staining with CPA quantification performed by ImageScope. Clinical outcomes, including total mortality, LRD, and combined liver outcomes (liver decompensation, HCC, or LRD), were determined by medical records and population-based data-linkage. The accuracy of CPA for predicting outcomes was compared with non-invasive fibrosis tests (Hepascore, FIB-4, APRI). RESULTS: A total of 295 patients (mean age 50 years) were followed for a median (range) of 9 (0.2–25) years totalling 3253 person-years. Patients with CPA ≥ 10% had significantly higher risks for total death [hazard ratio (HR): 5.0 (1.9–13.2)], LRD [19.0 (2.0–182.0)], and combined liver outcomes [15.6 (3.1–78.6)]. CPA and pathologist fibrosis staging (FS) showed similar accuracy (AUROC) for the prediction of total death (0.68 vs. 0.70), LRD (0.72 vs. 0.77) and combined liver outcomes (0.75 vs. 0.78). Non-invasive serum markers Hepascore, APRI, and FIB-4 reached higher AUROC; however, they were not statistically significant compared to that of CPA except for Hepascore in predicting total mortality (0.86 vs. 0.68, p = 0.009). CONCLUSION: Liver fibrosis quantified by CPA analysis was significantly associated with clinical outcomes including total mortality, LRD, and HCC. CPA achieved similar accuracy in predicting outcomes compared to pathologist fibrosis staging and non-invasive serum markers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12072-023-10564-3. Springer India 2023-06-26 /pmc/articles/PMC10522738/ /pubmed/37358741 http://dx.doi.org/10.1007/s12072-023-10564-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Wang, Zhengyi
Jeffrey, Gary P.
Huang, Yi
De Boer, Bastiaan
Garas, George
Wallace, Michael
Bertot, Luis
Adams, Leon A.
Liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease
title Liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease
title_full Liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease
title_fullStr Liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease
title_full_unstemmed Liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease
title_short Liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease
title_sort liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522738/
https://www.ncbi.nlm.nih.gov/pubmed/37358741
http://dx.doi.org/10.1007/s12072-023-10564-3
work_keys_str_mv AT wangzhengyi liverfibrosisquantifiedbyimagemorphometrypredictsclinicaloutcomesinpatientswithnonalcoholicfattyliverdisease
AT jeffreygaryp liverfibrosisquantifiedbyimagemorphometrypredictsclinicaloutcomesinpatientswithnonalcoholicfattyliverdisease
AT huangyi liverfibrosisquantifiedbyimagemorphometrypredictsclinicaloutcomesinpatientswithnonalcoholicfattyliverdisease
AT deboerbastiaan liverfibrosisquantifiedbyimagemorphometrypredictsclinicaloutcomesinpatientswithnonalcoholicfattyliverdisease
AT garasgeorge liverfibrosisquantifiedbyimagemorphometrypredictsclinicaloutcomesinpatientswithnonalcoholicfattyliverdisease
AT wallacemichael liverfibrosisquantifiedbyimagemorphometrypredictsclinicaloutcomesinpatientswithnonalcoholicfattyliverdisease
AT bertotluis liverfibrosisquantifiedbyimagemorphometrypredictsclinicaloutcomesinpatientswithnonalcoholicfattyliverdisease
AT adamsleona liverfibrosisquantifiedbyimagemorphometrypredictsclinicaloutcomesinpatientswithnonalcoholicfattyliverdisease